Qingfei Huoxue Decoction and Its Active Component Narirutin Alleviate LPS-Induced Acute Lung Injury by Regulating TLR4/NF-κB Pathway Mediated Inflammation
Yule Wang,Bei Li,Yingjuan Zhang,Ruiling Lu,Qianzhuo Wang,Yue Gao
DOI: https://doi.org/10.2147/jir.s480101
IF: 4.5
2024-10-22
Journal of Inflammation Research
Abstract:Yule Wang, &ast Bei Li, &ast Yingjuan Zhang, &ast Ruiling Lu, Qianzhuo Wang, Yue Gao Zhejiang Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Senile Chronic Diseases, Department of Geriatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yue Gao, Zhejiang Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Senile Chronic Diseases, Department of Geriatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, 261 huansha Road, Shangcheng District, Hangzhou, 310006, People's Republic of China, Email Background: Acute lung injury (ALI) is a life-threatening clinical syndrome with high mortality. Currently, the safe and effective therapies for ALI patients are still limited. Qingfei Huoxue decoction (QFHXD) is a hospital agreement prescription for treating pulmonary diseases and displays a remarkable efficacy. However, the pharmacological effect of QFHXD on preventing lipopolysaccharide (LPS)-induced ALI has yet to be reported, let alone questions of potential molecular mechanisms and anti-ALI active substances. Methods: To answer the above-mentioned questions, histopathological observation and kit detection were performed to estimate the protective effect of QFHXD pretreatment against LPS-induced ALI. Based on comprehensive chemical profiling of QFHXD, a network pharmacology strategy and experimental validation were integrated to elucidate the underlying functional mechanisms. The potential anti-ALI active components were identified by molecular docking. The anti-ALI activity of narirutin and its anti-inflammatory mechanism were further validated using animal and molecular experiments. Results: Pretreatment with different doses of QFHXD effectively mitigated histopathological lesions and systemic inflammation caused by LPS stimulation. A detailed analysis of established compound-target-disease network revealed the strong correlation between anti-ALI action of QFHXD and inflammatory mechanisms. Compared with the model group, QFHXD intervention markedly restrained the abnormally increased transcription and protein levels of pro-inflammatory factors (TLR4, NF-κB, IL-6, IL-1β, and TNF-α) in lung tissues of ALI mice. The results of molecular docking highlighted the anti-ALI potential of narirutin targeting to TLR4 and NF-κB p65. In addition to the protective effect of narirutin on suppressing LPS-induced pathological changes, we found that narirutin pretreatment effectively normalized the disordered protein levels of above pro-inflammatory factors of ALI mice. Conclusion: These interesting findings indicate the beneficial effects of QFHXD and its active component narirutin against ALI partly via regulating TLR4/NF-κB mediated inflammation. This work contributes to the development of novel medications for ALI patients. Keywords: Qingfei Huoxue decoction, narirutin, LPS-induced acute lung injury, network pharmacology, TLR4/NF-κB pathway, inflammatory response Graphical Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are the leading causes of acute respiratory failure in critically ill patients with high morbidity and poor clinical outcomes. 1 Especially, with the outbreak of the Coronavirus Disease 2019 (COVID-19), ALI/ARDS significantly contributes to the mortality in patients with COVID‐19. 2 As a major clinical problem worldwide, a variety of pulmonary and extra-pulmonary triggers accelerate the onset of ALI, such as pneumonia, pulmonary contusion, non-pulmonary sepsis, severe trauma with shock, and transfusion-related ALI. 3 The pathological characteristics of ALI are mainly manifested by diffuse alveolar damage with dysfunction of alveolar epithelial-capillary endothelial barrier, pulmonary edema, local inflammatory accumulation (activation of immune cells and production of pro-inflammatory mediators), eventually resulting in severe lung consolidation. 1,4 To date, apart from the recommended non-pharmacological intervention (lung-protective mechanical ventilation), corticosteroids, phosphodiesterase inhibitors, and neuromuscular blockers appear to be the most promising medications. 5,6 However, the limited options and medical burden urgently call for the novel therapeutic approaches. In China, Chinese medicines (CMs) have a long history in the clinical practice of ALI. 7 From the perspective of traditional Chinese medicine (TCM), the main pathogenesis of ALI can be summarized as heat, toxin, phlegm, and stasis -Abstract Truncated-
immunology